Advantage Investment Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Advantage Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-41	Closed	-$1K	–	999
2018 Q4	$1K	Hold	41	–	–	﹤0.01%	973
2018 Q3	$1K	Sell	41 -1,814	-98%	-$42.1K	﹤0.01%	990
2018 Q2	$45K	Sell	1,855 -22,374	-92%	-$456K	0.03%	386
2018 Q1	$414K	Buy	24,229 +781	+3%	+$15.2K	0.16%	113
2017 Q4	$444K	Buy	23,448 +23,114	+6,920%	+$348K	0.14%	118
2017 Q3	$6K	Sell	334 -24,745	-99%	-$557K	﹤0.01%	797
2017 Q2	$833K	Buy	25,079 +2,754	+12%	+$85.2K	0.29%	76
2017 Q1	$716K	Buy	22,325 +2,248	+11%	+$76.7K	0.28%	79
2016 Q4	$728K	Buy	20,077 +20,036	+48,868%	+$800K	0.27%	75
2016 Q3	$2K	Hold	41	–	–	﹤0.01%	841
2016 Q2	$2K	Hold	41	–	–	﹤0.01%	797
2016 Q1	$2K	Hold	41	–	–	﹤0.01%	787
2015 Q4	$3K	Hold	41	–	–	﹤0.01%	749
2015 Q3	$2K	Hold	41	–	–	﹤0.01%	760
2015 Q2	$2K	Buy	+41	New	+$2.53K	﹤0.01%	795

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advantage Investment Management's TEVA Position: Q1 2019 in Review

Advantage Investment Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2019, closing a stake of 41 shares — an estimated $1K sold.

Advantage Investment Management first reported a position in TEVA in Q2 2015 and held it in 15 quarters. The position peaked at $833K in Q2 2017. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

Advantage Investment Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2019 after selling out during the quarter.
Advantage Investment Management sold 41 Teva Pharmaceutical Industries Limited shares in Q1 2019, an estimated $1K.
Advantage Investment Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2015 and held it in 15 quarters.
Advantage Investment Management's Teva Pharmaceutical Industries Limited position peaked at $833K in Q2 2017.
522 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2019.

Based on Advantage Investment Management's 13F filing for Q1 2019, filed 15 May 2019.